Hangzhou and Shaoxing, China, 10 March 2020 -- Ascletis Pharma Inc. (HKEX code：1672) announces today the progress of the small sample clinical trial of Ganovo® and Ritonavir combination therapy on Novel Coronavirus Pneumonia. One of the treatment groups in this study is the group receiving oral Ganovo® and Ritonavir combination therapy, in which 10 Novel Coronavirus Pneumonia patients were planned to be enrolled, and 11 patients actually enrolled. All of 11 patients receiving oral Ganovo® and Ritonavir combination therapy have been discharged as they are satisfied with the discharge standards under the “Diagnosis and Treatment Program for Novel Coronavirus Infection (Trial Version 6)” issued by the National Health Commission of the People’s Republic of China.
This small sample clinical trial of oral Ganovo® and Ritonavir combination therapy (NCT04291729), led by Dr. Hongyi CHEN, the director of the Ninth Hospital of Nanchang, obtained approval from the ethics committee of the Ninth Hospital of Nanchang on February 16, 2020.
“We are pleased that our anti-viral drugs are contributing to fighting the epidemic of novel coronavirus and curing patients.” said Dr. Jinzi J. Wu, Founder, Chairman and CEO of Ascletis.
Ascletis is an innovative R&D driven biotech with two commercial products and listed on Hong Kong Stock Exchange (Ascletis, 1672.HK). Ascletis is committed to developing and commercializing antiviral, steatohepatitis, and tumor-related innovative drugs for unmet medical needs in China and Globally. Led by a management team with deep expertise and a proven track record, Ascletis has developed into a fully integrated platform covering the entire value chain from discovery and development to manufacturing and commercialization. Ascletis' pipeline is focused primarily on three therapeutic areas: 1. HCV: one commercial stage product, one near commercial stage drug and two R&D stage drug candidates. Ganovo® (Danoprevir) is the first direct-acting anti-viral agent for hepatitis C, developed by a domestic firm in China. 2. HBV: one commercial stage product and three R&D stage drug candidates. Pegasys® (Peginterferon alfa-2a) is a leading marketed pegylated interferon for hepatitis B&C partnered with Roche. 3. NASH (Non-Alcoholic SteatoHepatitis): three R&D stage drug candidates against three different targets for combination treatments. For more information, please visit www.ascletis.com.
Ascletis Pharma Inc.
Chenlin Li, +86-159-6815-8530